Unique ID issued by UMIN | UMIN000012071 |
---|---|
Receipt number | R000013631 |
Scientific Title | The combination therapy of HAIC and RT for tumor thrombosis. |
Date of disclosure of the study information | 2013/10/18 |
Last modified on | 2019/03/20 14:30:57 |
The combination therapy of HAIC and RT for tumor thrombosis.
The combination therapy of HAIC and RT for tumor thrombosis.
The combination therapy of HAIC and RT for tumor thrombosis.
The combination therapy of HAIC and RT for tumor thrombosis.
Japan |
Hepatocellular carcinoma
Medicine in general | Hepato-biliary-pancreatic medicine |
Malignancy
NO
prognosis
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
Local tumor control rate
Overall survival rate
Observational
20 | years-old | <= |
90 | years-old | > |
Male and Female
1) 20 Years and older.
2) Life expectancy of at least 12 weeks at the pre-treatment evaluation.
3) Advanced hepatocellular carcinoma with histological evidence on a biopsy specimen, or typical findings by dynamic CT or MRI.
4) Not suitable for resection or local ablation therapy or transcatheter arterial chemoembolization.
5) At least 4 weeks since last therapy for HCC.
6) Intrahepatic tumor which affects patient'prognosis.
7) Extrahepatic tumor apread which not affects patient's prognosis.
8) ECOG Performance status of 0 or 1.
9) Child-Pugh 5,6,7
10) Adequate bone marrow, liver and renal function, as assessed by the following laboratory requirements:
Granulocyte >= 3000/mm3
Platelet count >= 50,000 /mm3 Hemoglobin >= 8.5 g/dl
Total serum bilirubin <= 3 mg/dl
serum albimin>=2.8
Serum creatinine <= 1.5 mg/dl
prothrombin consumption test>=50%
Amylase <= 2 times upper limit of normal
11) Written Informed Consent must be obtained.
1) With other malignant disease.
2) A pregnant woman, or a woman suspected of pregnancy.
3) With severe infectious disease.
4) With history of severe allergy.
5) With severe renal function disease. 6) With severe allergy for 5FU or CDDP.
7) With severe bone marrow supression.
8) Esophageal and/or gastric varices which has high risk of bleeding and clinically significant gastro-
intestinal bleeding.
9) Serious hypertension
10) Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment.
70
1st name | |
Middle name | |
Last name | kazuaki Chayama |
Hiroshima university hospital
Departments of Gastroenterology and Metabolism
1-2-3 Kasumi, Minamiku, Hiroshima
082-257-5192
Chayama@hiroshima-u.ac.jp
1st name | |
Middle name | |
Last name | Hiroshi Aikata |
Hiroshima university hospital
Departments of Gastroenterology and Metabolismepartments of Gastroenterology and Metabolism
1-2-3 Kasumi, Minamiku, Hiroshima
082-257-5192
aikata@hiroshima-u.ac.jp
Hiroshima university hospital
Hiroshima university hospital
Other
NO
2013 | Year | 10 | Month | 18 | Day |
Unpublished
Completed
2013 | Year | 09 | Month | 10 | Day |
2013 | Year | 10 | Month | 07 | Day |
2013 | Year | 11 | Month | 01 | Day |
2016 | Year | 09 | Month | 30 | Day |
2017 | Year | 09 | Month | 30 | Day |
2017 | Year | 09 | Month | 30 | Day |
2017 | Year | 09 | Month | 30 | Day |
We perform radiotherapy as additional treatment combined with HAIC for hepatocellular carcinoma tumor thrombosis. Further we examine the effectiveness and safety and follow up them after this treatment.
2013 | Year | 10 | Month | 18 | Day |
2019 | Year | 03 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013631
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |